Jeffrey Gerald Mifek - 06 Jul 2026 Form 4 Insider Report for FEMASYS INC (FEMY)

Reporting relationship: Chief Clinical-Medical Affairs
Issuer ticker: FEMY
Reported as of: 06 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Aug 2026, 20:51:06 UTC
Next SEC filing: 11 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Kathy Lee-Sepsick, Attorney-in-fact

Key filing fact

Jeffrey Gerald Mifek filed Form 4 for FEMASYS INC (FEMY) on 11 Aug 2026.

Key facts

This page summarizes Jeffrey Gerald Mifek's Form 4 filing for FEMASYS INC (FEMY).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Aug 2026, 20:51.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002143295 Primary reporting owner

Mifek Jeffrey Gerald

Relationship: Chief Clinical-Medical Affairs
Address: C/O FEMASYS INC., 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE
Signature: /s/ Kathy Lee-Sepsick, Attorney-in-fact
Signature date: 11 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FEMY transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +6,250
Change %
Price: $0.000000^*
Shares after: 6,250
Date: 06 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,250
Exercise price: $4.08
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying the stock option vest equally in installments over 4 years beginning on July 6, 2027, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date.